Neuphoria Therapeutics (NEUP) Stock Analysis
NASDAQHealthcareBiotechnology
What Neuphoria Therapeutics does
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Key metrics
ETFs linked to NEUP
Broad-market and Healthcare sector ETFs an investor holding Neuphoria Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how NEUP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze NEUP in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Neuphoria Therapeutics?
- Neuphoria Therapeutics trades under the ticker NEUP on NASDAQ.
- Which exchange is NEUP listed on?
- NEUP is listed on NASDAQ.
- What sector does Neuphoria Therapeutics operate in?
- Neuphoria Therapeutics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze NEUP in a portfolio?
- PortView shows NEUP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.